07:06am Sunday 24 September 2017

Ob-Gyns Respond to High Cost of Makena™

Washington, DC — The American College of Obstetricians and Gynecologists (The College), along with the American Academy of Pediatrics and the Society for Maternal-Fetal Medicine, is urging Ther-Rx Corporation to reconsider its pricing of Makena™. Makena is the first FDA-approved medication to help prevent preterm birth in certain high-risk pregnant women. The College argues that the extremely high cost of Makena™ will hinder access and affordability to this treatment for both insured and uninsured patients.

To read the full letter, go to http://www.acog.org/from_home/misc/20110311GoedekeLtr.pdf

 

# # #

The American College of Obstetricians and Gynecologists (www.acog.org) is the nation’s leading group of physicians providing health care for women. As a private, voluntary, nonprofit membership organization of approximately 55,000 members, The American College of Obstetricians and Gynecologists strongly advocates for quality health care for women, maintains the highest standards of clinical practice and continuing education of its members, promotes patient education, and increases awareness among its members and the public of the changing issues facing women’s health care. Follow us on Twitter at www.twitter.com/acognews.


Share on:
or:

MORE FROM Pregnancy and Childbirth

Health news